Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) [Phase 3]

View source ↗

Summary

Merck's pneumococcal vaccine V116 completed a Phase 3 trial (STRIDE-4) in adults 18 to 49 years, assessing safety, tolerability, immunogenicity, and lot consist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-05-24